Vifor Pharma released a good set of FY17 results in which revenue and profitability came in ahead of our expectations. Total revenue surged by 15% (190bp above AV’s estimate vs. guidance of >10%) led by strong growth momentum in the intravenous/IV iron drug franchisee. Vifor’s flagship product ‘Ferinject/Injectafer’ grew 24.6% (c.32% of sales) on the back of robust demand in the US (+35%; c.21% of drugs sales) and Europe (+17%). Although sales for Venofer slumped 11
28 Mar 2018
Strong finish to the year; heightened competition in FY18
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong finish to the year; heightened competition in FY18
Galenica AG (0ROG:LON) | 0 0 0.0% | Mkt Cap: 2,446m
- Published:
28 Mar 2018 -
Author:
Sumit Sayal -
Pages:
4
Vifor Pharma released a good set of FY17 results in which revenue and profitability came in ahead of our expectations. Total revenue surged by 15% (190bp above AV’s estimate vs. guidance of >10%) led by strong growth momentum in the intravenous/IV iron drug franchisee. Vifor’s flagship product ‘Ferinject/Injectafer’ grew 24.6% (c.32% of sales) on the back of robust demand in the US (+35%; c.21% of drugs sales) and Europe (+17%). Although sales for Venofer slumped 11